Boehringer Ingelheim Pharmaceuticals has announced the availability of the Stiolto Respimat tiotropium bromide/olodaterol soft mist inhaler in the United States. Stiolto Respimat was approved by the FDA for the treatment of COPD in May 2015.
Pharmacies are selling the inhaler for about $325-$350. The company is offering a savings card to cover a co-pays over 12 months for patients who have commercial insurance and refers patients without insurance who cannot afford to purchase inhalers to its patient assistance program,
Boehringer Ingelheim Pharmaceuticals Senior VP, Marketing, Kathleen M. Dowd commented, “For more than 40 years, Boehringer Ingelheim has been an industry leader in the discovery and development of new treatment options for the COPD community. In fact, we began our scientific research of COPD when there were no available options, and now offer six therapies for people living with this chronic disease. We are proud to offer patients Stiolto Respimat, which has proven to be more effective in improving lung function than either tiotropium or olodaterol alone, with a comparable safety profile.”
Read the Boehringer Ingelheim press release.
